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Abstract
Background: Current treatment of chronic hepatitis C virus (HCV) infection has limited efficacy 2especially among
genotype 1 infected patients2, is costly, and involves severe side effects. Thus, predicting non-response is of major interest
for both patient wellbeing and health care expense. At present, treatment cannot be individualized on the basis of any
baseline predictor of response. We aimed to identify pre-treatment clinical and virological parameters associated with
treatment failure, as well as to assess whether therapy outcome could be predicted at baseline.
Methodology: Forty-three HCV subtype 1b (HCV-1b) chronically infected patients treated with pegylated-interferon alpha
plus ribavirin were retrospectively studied (21 responders and 22 non-responders). Host (gender, age, weight, transaminase
levels, fibrosis stage, and source of infection) and viral-related factors (viral load, and genetic variability in the E1–E2 and
Core regions) were assessed. Logistic regression and discriminant analyses were used to develop predictive models. A
‘‘leave-one-out’’ cross-validation method was used to assess the reliability of the discriminant models.
Principal Findings: Lower alanine transaminase levels (ALT, p=0.009), a higher number of quasispecies variants in the E1–
E2 region (number of haplotypes, nHap_E1–E2) (p=0.003), and the absence of both amino acid arginine at position 70 and
leucine at position 91 in the Core region (p=0.039) were significantly associated with treatment failure. Therapy outcome
was most accurately predicted by discriminant analysis (90.5% sensitivity and 95.5% specificity, 85.7% sensitivity and 81.8%
specificity after cross-validation); the most significant variables included in the predictive model were the Core amino acid
pattern, the nHap_E1–E2, and gamma-glutamyl transferase and ALT levels.
Conclusions and Significance: Discriminant analysis has been shown as a useful tool to predict treatment outcome using
baseline HCV genetic variability and host characteristics. The discriminant models obtained in this study led to accurate
predictions in our population of Spanish HCV-1b treatment naı ¨ve patients.
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Introduction
Hepatitis C virus (HCV), with an estimated 170 million people
infected worldwide, is the major causative agent of chronic liver
disease, cirrhosis and hepatocellular carcinoma [1]. HCV is an
enveloped positive single-stranded RNA virus and its genome
exhibitssignificant geneticvariability, which hasbeen used to classify
the virus into six major genotypes and a number of subtypes [2].
Furthermore, a high replication rate and the lack of proofreading
activity of the viral RNA-dependent RNA polymerase generate a
dynamic mosaic of closely related variants, usually referred to as
quasispecies, within an infected individual. This phenomenon allows
chronic infection establishment and may also have important
implications in pathogenicity and resistance to antiviral drugs [3].
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combination therapy constitutes the current standard of care for
chronic hepatitis C treatment [4]. Despite recent advances in the
development of ‘‘specifically targeted antiviral therapy for hepatitis
C’’ (STAT-C) compounds, with protease inhibitors in phase III
studies, possible future treatment regimens are likely to continue
including these drugs in order to prevent HCV resistance [5].
Combination treatment is costly, requires long-term follow-up,
and involves severe side effects. Furthermore, HCV genotype 1
infected patients fail to achieve a sustained virological response
(SVR) in about 40–50% of the cases [6,7]. Genotype 1 is the most
common genotype worldwide; HCV subtype 1b (HCV-1b) is the
most prevalent in Southern and Eastern Europe, Japan and other
countries [8,9] and is associated with a higher risk for
hepatocellular carcinoma development [10].
A number of host-related factors have been associated with a
lower likelihood of response to treatment, such as African-
American ancestry, advanced liver fibrosis or cirrhosis, older
age, male gender, obesity, transaminase levels, and host genetic
polymorphisms [6,7,11–18]. Among the later, the rs12979860
polymorphism near the IL28B gene is the strongest predictive
factor of SVR identified so far [14]; however, European-American
patients not having the most favourable genotype (C/C) still have
approximately 40% chance of responding to therapy (negative
predictive value (NPV) around 60%). With regards to baseline
virological factors, high viral loads, high levels of genetic variability
within the E1–E2 and NS5A regions, as well as mutations in the
so-called interferon sensitivity determining region (ISDR) and
Core regions, have been related to therapeutic failure. Neverthe-
less, such findings have not been found in other studies and remain
controversial [11,19].
As predicting non-response prior to treatment is of major
interest for both patient wellbeing and health care expense, several
predictive models with variable accuracy have been proposed for
HCV-1, such as those based in clinical variables in combination
with viral load [20] or the ISDR mutant [21], as well as amino
acid covariance in the full viral coding region [22]. However,
according to present guidelines for patient management, individ-
ual treatment outcomes can only be precisely predicted once
treatment is initiated on the basis of viral kinetics; a $2-Log(HCV-
RNA) decline at week 12 (early virological response) is the most
robust approach for identifying non-responder patients (NPV, 97–
100%) and thus constitutes the earliest treatment-stopping rule [4].
The goal of this study was to identify pre-treatment clinical and
virological parameters associated with treatment failure, as well as
to assess whether therapy outcome could be predicted at baseline
by means of comprehensive statistical methods in HCV-1b
treatment naı ¨ve patients. Our results show that discriminant
analysis could be a useful tool to predict treatment outcome using
both baseline HCV genetic variability and host characteristics.
The discriminant models obtained in this study lead to accurate
predictions in our population of Spanish HCV-1b patients.
Results
Treatment response groups and adherence
Forty-three white Spanish patients met the inclusion criteria, 21
being responders and 22 non-responders. All patients were on
treatment for the complete expected time and adherence to both
drugs was overall .80%. No significant differences were observed
between groups: 20 (95.2%) and 22 (100%) responders and non-
responders had a good adherence to PegIFN-a, respectively
(p=0.488), and these proportions were 17 (80.9%) and 20 (90.9%)
for RBV (p=0.412).
Baseline clinical variables associated with treatment
outcome
Baseline clinical characteristics of patients according to
treatment outcome and bivariate analyses results are shown in
Table 1. Responder and non-responder groups were comparable
in terms of gender, age, source of infection, and liver fibrosis stage
(liver biopsy was not performed in 37.2% of the patients).
Regarding body weight, one outlier was identified corresponding
to a responder patient with 101.40 Kg, and differences between
groups became significant when this patient was excluded
(70.7968.35 vs. 78.51614.96 Kg in responder and non-respond-
er groups, respectively p=0.048). The alanine transaminase (ALT)
quotient was significantly higher in responders than in non-
Table 1. Baseline clinical features of study patients according to treatment response group.
Patient characteristic Responders (n=21) Non-responders (n=22) p-value
Male gender, n (%) 9 (42.9) 14 (63.6) 0.172
Age
a 47.5269.66 48.55612.39 0.764
Weight (Kg)
a 72.24610.53 78.51614.96 0.122
Source of infection, n (%) Blood transfusion 6 (28.6) 10 (45.5) 1.000
Non blood transfusion 2 (9.5) 2 (9.1)
Unknown 13 (61.9) 10 (45.5)
Liver fibrosis stage, n (%) F0-2 11 (52.3) 10 (45.5) 0.648
F3-4 2 (9.5) 4 (18.2)
Unknown 8 (38.1) 8 (36.4)
ALT quotient (6ULN)
b 2.51 (1.32–4.15) 1.53 (0.15–4.90) 0.009
AST quotient (6ULN)
a 1.7460.50 1.5460.74 0.328
GGT quotient (6ULN)
b 0.58 (0.22–1.80) 1.12 (0.18–2.50) 0.111
ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma-glutamyl transferase; 6ULN, factor times upper limit of normal used in our center for males and
females: 41 and 31 U/L for ALT, 37 and 31 for AST, and 85 and 50 for GGT, respectively;
aData presented as mean 6 SD, Student’s t test;
bData presented as median (range), Mann-Whitney U test.
doi:10.1371/journal.pone.0014132.t001
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ase (GGT) quotient tended to be higher in the non-responder
group; two outliers were identified, which corresponded to two
responder patients, and the GGT quotient was significantly higher
in the non-responder group when these outliers were excluded
(median, 0.58 and 1.07 in responders and non-responders,
respectively, p=0.033). The aspartate transaminase (AST) quo-
tient was similar in both groups.
Baseline virological variables associated with treatment
outcome
HCV viral load. Viral load did not differ significantly
between groups (p=0.210), with a mean value of
5.7560.86 Log(IU/ml) in responders, and 6.0360.58 Log(IU/
ml) in non-responders.
E1–E2 genetic variability estimates. The median number
of clones sequenced per patient was 22 (range, 20–33) in
responders and 23 (range, 20–27) in non-responders (p=0.291),
yielding a total of 993 sequences. Genetic variability estimates
according to treatment outcome and genomic region are shown in
Table 2. Although non-responder patients tended to have higher
values than those with SVR for most E1–E2 genetic variability
estimates, the number of quasispecies variants (number of
haplotypes, nHap) was the only factor that significantly differed
between groups (p=0.003). Regarding the hypervariable regions
(HVR), the HVR-1 showed the highest values for all parameters;
the nHap and the number of synonymous substitutions per
synonymous site (Ks) in this region were marginally significant,
both being higher in non-responders.
Phylogenetic analysis of the E1–E2 region. Differentiated
clusters corresponding to responder and non-responder patients
were not observed (Figure S1). Patients 1746 and 3468 appeared
to be closely epidemiologically related since they shared a
monophyletic clade with a 100% bootstrap support. In this
clade, sequences from patient 1746 were a subgroup of those
obtained from patient 3468, thus pointing to a source-recipient
relationship. Patients 1634 and 3030, and 587 and 1313 might also
be epidemiologically related, as inferred from the highly supported
clade encompassing sequences from both patients in each group
(100 and 90% bootstrap values, respectively), but no source-
recipient relationship could be inferred.
Analysis of amino acid composition of the E1–E2
region. None of the nine amino acid positions initially
identified by VESPA analysis showed a significantly different
composition between responders and non-responders after the
false discovery rate correction was applied (data not shown).
Analysis of amino acid composition of the Core
region. VESPA analysis did not identify any amino acid
position that differed between groups, although a polymorphism
at position 70 was detected. On the other hand, when pairs of
observed polymorphisms were subjected to bivariate analysis, the
absence of both amino acids arginine (R) at position 70 and
leucine (L) at position 91 was observed in 5 of 21 responder
patients (23.8%) and in 12 of 22 non-responders (54.5%),
(p=0.039). R70 was substituted either by glutamine (Q) or
histidine (H), and L91 mostly by methionine (M) and by cysteine
(C) in one case. Since phylogenetic analysis showed that patients
with this amino acid pattern did not group within the same cluster,
the observed association was not attributed to sharing a common
ancestry. This phylogenetic analysis provided similar evidence
regarding to epidemiological relationships described for the E1–E2
region (data not shown).
Prediction of the treatment outcome according to
baseline host and virological variables
Logistic regression analysis. Variables showing a p-value
,0.2 in the bivariate analyses (gender, Sqrt(ALT quotient),
Sqrt(GGT quotient), weight, Core amino acid pattern, nHap_
E1–E2, Log(Ks_E1–E2), nHap_HVR-1, and Sqrt(Ks_HVR-1))
were initially considered; the nHap_E1–E2 and the Core amino
acid pattern persisted in the final model (Text S1), with an odds
ratio (OR) of 1.47 (95% confidence interval, CI95%=[1.16–1.87])
and 25.47 (CI95%=[2.52–257.74]), respectively. Thus, the
absence of amino acids R70 and L91 and a higher nHap_E1–
E2 significantly increased the risk for treatment failure. An area
under the curve (AUC) of 0.8755 was obtained in the receiver
operating characteristic (ROC) curve (Figure 1), and selecting a
0.500 cut-off yielded a sensitivity and positive predictive value
(PPV) of 81.0%, and a specificity and NPV of 81.8%.
Table 2. Summary of viral genetic variability estimates according to genomic region.*
E1–E2 region HVR-1 subregion HVR-2 subregion HVR-3 subregion
Estimator
Responders
(n=21)
Non-
responders
(n=22)
p-
value
Responders
(n=21)
Non-
responders
(n=22)
p-
value
Responders
(n=21)
Non-
responders
(n=22)
p-
value
Responders
(n=21)
Non-
responders
(n=22)
p-
value
S 60.9642.9 68.0626.7 0.525 16.0 (1–48) 17.0 (0–46) 0.319 3.0 (0–13) 4.0 (1–10) 0.366 13.7610.2 13.166.9 0.817
g 48.0 (9–154) 63.5 (29–142) 0.290 17.0 (1–64) 18.0 (0–59) 0.458 3.0 (0–13) 4.0 (1–11) 0.282 11.0 (2–42) 12.0 (5–34) 0.981
nHap 17 (5–25) 22 (11–27) 0.003 11 (2–17) 12 (1–18) 0.090 4 (1–12) 5 (2–10) 0.281 9.565.4 10.863.4 0.384
p 0.019
(0.002–0.089)
0.024
(0.005–0.077)
0.496 0.043
(0.001–0.261)
0.063
(0.000–0.256)
0.716 0.035
(0.000–0.186)
0.032
(0.003–0.176)
0.734 0.019
(0.001–0.132)
0.021
(0.005–0.099)
0.923
Ka 0.013
(0.000–0.063)
0.014
(0.001–0.060)
0.827 0.052
(0.000–0.294)
0.057
(0.000–0.279)
0.903 0.030
(0.000–0.195)
0.028
(0.000–0.221)
0.961 0.016
(0.000–0.084)
0.009
(0.001–0.084)
0.536
Ks 0.05760.050 0.06460.035 0.609 0.07060.060 0.11260.079 0.064 0.041
(0.000–0.591)
0.048
(0.000–0.190)
0.864 0.040
(0.004–0.322)
0.056
(0.014–0.162)
0.610
*Nucleotide positions corresponding to the H77 reference sequence (GenBank accession number AF009606): E1–E2 region, 1322–1853; HVR-1, 1491–1571; HVR-2, 1761–
1787; HVR-3, 1632–1739.
S, total number of polymorphic sites; g, total number of mutations; nHap, number of haplotypes; p, nucleotide diversity corrected by Jukes-Cantor method; Ka, number
of nonsynonymous substitutions per nonsynonymous site; Ks, number of synonymous substitutions per synonymous site; Data are expressed as mean 6 SD, Student’s t
test or median (range), Mann-Whitney U test.
doi:10.1371/journal.pone.0014132.t002
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obtained (Text S1) and cross-validated to assess how the results
obtained would generalize to an independent but similar data set.
Variables that persisted in Model 1 were: Core amino acid
pattern, nHap_E1–E2, Sqrt(GGT quotient), Sqrt(ALT quotient),
Log(viral load), Sqrt(total number of polymorphic sites in the
HVR-2, S_HVR-2), body weight, and Log(Ks_E1–E2), in
decreasing order of significance. The ROC curve obtained had
an AUC of 0.9946 (Figure 1). This model yielded a 95.2%
sensitivity and a 100% specificity (Table 3); however, sensitivity
decreased to 76.2% and specificity to 72.7% after cross-
validation. Therefore, we developed model 2 including the
Core amino acid pattern, nHap_E1–E2, Sqrt(GGT quotient),
Sqrt(ALT quotient), nHap_HVR-1, and Sqrt(Ks_HVR-1), and
body weight, in decreasing order of significance. The AUC of the
corresponding ROC curve was 0.9697 (Figure 1). Treatment
outcome was predicted with 90.5% sensitivity and 95.5%
specificity (cut-off, 0.550), and these values remained high after
the cross-validation (85.7% and 81.8%, respectively). Besides, the
model could be optimized to correctly identify most responder
patients by choosing a cut-off of 0.900, so that treatment is not
denied to individuals that are likely to respond (NPV, 93.3% after
cross-validation). Sensitivity, specificity, NPV and PPV for
different cut-offs are shown in Table 3. According to cross-
validation, in an independent but similar data set, treatment
could be omitted in 63.6 to 81.8% of the non-responder patients
while most patients likely to respond would be identified and
treated.
Discussion
As combination treatment failure occurs in about half of all
patients with chronic hepatitis C infected by genotype 1 [6,7],
prediction of treatment outcome at baseline would be highly
beneficial. Although several factors have been identified as
predictors of treatment outcome, none of them can provide a
reliable individualized prediction when used independently. Based
on our results in Spanish patients infected with HCV-1b, we
propose the use of discriminant statistical models based on host
and viral characteristics to provide an aggregate prediction of the
treatment outcome at baseline.
Among the host-related factors studied baseline ALT levels,
which are an indicator of liver damage, were significantly higher in
responder patients than in non-responders (p=0.009), as previ-
ously reported [11,12]. Conversely, the GGT quotient tended to
be higher in the non-responder group in agreement with other
studies [12,23]; higher GGT levels have been related to advanced
fibrosis, steatosis and insuline resistance, which are more common
among non-responders [24]. The body weight tended to be higher
in non-responder patients; in fact, it has been suggested that obese
subjects have an increased expression of the IFN-a signalling
inhibitor factor SOCS-3 [25]. Some of the host factors that have
previously been associated with treatment failure, such as male
gender, advanced age, advanced liver fibrosis stage and cirrhosis
[6,7,13] did not reach statistical significance in our study probably
due to a limited sample size, especially regarding the liver biopsy,
which was not performed in 37.2% of patients.
Figure 1. Receiver operating characteristic (ROC) curves for the multivariate logistic regression analysis and discriminant analysis
models. AUC, area under the ROC curve; Sensitivity, proportion of responders which are correctly identified; Specificity, proportion of non-
responders which are correctly identified. Variables included in the models in decreasing order of significance: logistic regression model, Core amino
acid pattern and nHap_E1–E2; discriminant analysis model 1, Core amino acid pattern, nHap_E1–E2, Sqrt(GGT quotient), Sqrt(ALT quotient), Log(viral
load), Sqrt(S_HVR-2), body weight, and Log(Ks_E1–E2); discriminant analysis model 2, Core amino acid pattern, nHap_E1–E2, Sqrt(GGT quotient),
Sqrt(ALT quotient), nHap_HVR-1, and Sqrt(Ks_HVR-1), and body weight.
doi:10.1371/journal.pone.0014132.g001
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been suggested as a predictor of SVR, but several cut-offs have
been proposed [24]. In our study, average viral loads were higher
in non-responders but differences were not significant. Addition-
ally, several studies have reported an association between the level
of variability in the HCV genome at baseline and treatment
outcome. Envelope glycoprotein coding regions are highly
variable; the HVR-1, which is the most variable region in the
whole genome, is targeted by host neutralizing antibodies and
plays a role in immune escape [26]. While the variability in this
region has also been associated with treatment outcome [27–32],
discrepancies on this matter have been noted probably due to the
different treatment regimens, the different genetic variability
estimates employed, and limitations in statistical analyses [33–
35]. While our results show that treatment outcome was not
related to the presence of a common evolutionary origin, in
general terms, the E1–E2 genetic variability estimators suggested
that a high heterogeneity in the baseline viral population could be
involved in combination therapy failure, either through the pre-
existence or the generation of drug-resistant viral variants. A
higher number of quasispecies variants in the E1–E2 region
(nHap_E1–E2) was significantly associated with treatment failure
(p=0.003). Additionally, when the analysis focussed on the HVR-
1 subregion, nHap and Ks were marginally significant with higher
values in the non-responder group. Although significant differ-
ences between groups at the amino acid level were not found,
synonymous substitutions may have an effect on the secondary
structure of the genomic RNA, which is an important selection
target [36].
Pre-treatment Core amino acid substitutions at positions 70 (R
by Q) and/or 91 (L by M) have been described as useful
independent predictors of treatment failure in Japanese HCV-1b
infected patients [37]. Similarly, our results show an association
between the absence of both R70 and L91 amino acids and
treatment failure (p=0.039). Although it has been suggested that
the Core protein may inhibit the transcription of antiviral genes
induced by IFN-a [38], further studies are needed to clarify the
role of the observed amino acid substitutions in treatment failure.
Since factors that significantly differed between groups in the
bivariate analyses were not completely reliable in predicting
treatment outcome when used independently, we developed
predictive models that included a combination of variables. The
logistic regression analysis identified the nHap_E1–E2 (OR=1.47)
and the Core amino acid pattern (OR=25.47) as independent risk
factors for treatment failure. However, predictive models obtained
by discriminant analysis including additional variables showed
better AUC values and more accurate predictions in our study
population (90.5–95.2% sensitivity and 95.5–100% specificity).
The most significant variables in both discriminant models were
the Core amino acid pattern, nHap_E1–E2, and GGT and ALT
quotients. Although prediction accuracy may deteriorate in an
independent sample, the internal cross-validation pointed to a
better reproducibility for model 2 in a comparable population
(identifying 85.7% and 81.8% of the responder and non-responder
patients, respectively), despite the fact that model 1 best predicted
treatment outcome in our population. Besides, using model 2 the
detection of those patients likely to respond to therapy could be
maximized by adjusting the cut-off, leading to a higher NPV at the
cost of a lower specificity (93.3% and 63.6%, respectively, after
cross-validation). Thus, the results suggest that non-response could
be predicted at baseline with high accuracy (NPV after cross-
validation of 81.8% to 93.3% depending on the cut-off) in patient
groups comparable to ours in terms of ethnicity, clinical
background, and HCV subtype.
To our knowledge, this is the first study that describes a model
for predicting individual combination therapy outcomes on the
basis of baseline host and viral characteristics using a discriminant
multivariate analysis. This comprehensive statistical method
integrates the information of all variables included in the model
thus improving the prediction with respect to more commonly
used statistical approaches. Additionally, discriminant models may
be adjusted to include the most significant predictors of treatment
outcome in each population. However, our study has several
limitations: i) other viral genome regions not included in the study
might also be involved in resistance to therapy, such as the ISDR.
Nevertheless, a meta-analysis suggested that the association
between the number of mutations in this region and SVR
achievement was more pronounced in Japanese than in European
patients [39]. As most European HCV-1b strains present less than
3 mutations, large sample sizes would be required to find
significant associations; ii) recent studies have suggested that single
nucleotide polymorphisms in several human genes involved in the
IFN mediated response are associated to treatment outcome in
HCV-1 infected patients, especially the IL28B gene polymor-
phisms [14–18]. Since our study was retrospective, whole-blood
samples were not available to assess host genetic polymorphisms;
iii) the sample size was limited to 43 patients. However, a similar
number of patients were included in each group, accounting for
the fact that about 50% of patients infected by HCV-1b achieve
an SVR. Although an independent but similar population was not
available, we performed an internal cross-validation. This method
is commonly used to reduce classification bias and estimate future
model performance [40].
Our results show that both host and viral factors are involved
in treatment failure, although the exact mechanisms should be
further characterized. The host-related variables included in the
prediction models are routinely used for patient management
and relatively easy to obtain, while viral variability estimates are
obtained through laborious methods. Even so, and if confirmed
in further studies, the information obtained may help physicians
to restrict treatment to those patients that are likely to benefit
from it, thus reducing overall treatment costs. Those patients
Table 3. Sensitivity, specificity, and predictive values for the discriminant models obtained.
AUC Cut-off
Sensitivity, % (cross-
validated)
Specificity, % (cross-
validated)
NPV, % (cross-
validated)
PPV, % (cross-
validated)
Model 1 0.9946 0.500 95.2 (76.2) 100 (72.7) 95.7 (76.2) 100 (72.7)
Model 2 0.9697 0.550 90.5 (85.7) 95.5 (81.8) 95.0 (81.8) 91.3 (85.7)
0.900 95.2 (95.2) 68.2 (63.6) 93.8 (93.3) 74.1 (71.4)
AUC, area under the receiver operating characteristic curve; PPV, positive predictive value; NPV, negative predictive value.
doi:10.1371/journal.pone.0014132.t003
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related side effects, and wait for more effective treatment
regimens.
In conclusion, discriminant analysis using both baseline HCV
genetic variability and host characteristics has been shown as a
useful statistical tool allowing us to accurately predict combination
treatment outcome in a high proportion of Spanish HCV-1b
infected patients. Further studies including host genetic polymor-
phisms and larger numbers of patients are under way, and
similarly generated models will probably have an increased
predictive power.
Materials and Methods
Ethics statement
This study was approved by the Clinical Research Ethics
Committee at our institution (‘‘Comite ´E ´tico de Investigacio ´n
Clı ´nica’’, CEIC). As this was a retrospective study, and data were
analyzed anonymously, informed consent was specifically waived.
Patients and specimens
Patients with chronic hepatitis C by HCV-1b, treated with
combination therapy at ‘‘Hospital Universitari Germans Trias i
Pujol’’, were retrospectively selected. Exclusion criteria were:
previous IFN-based treatment, HIV or HBV coinfection, and
having other causes of liver disease or alcohol abuse. Infection with
HCV-1b was confirmed through NS5B sequencing followed by
phylogenetic analysis, as previously described [41]. The patients
had started antiviral therapy with PegIFN-a2a (180 mg/week) plus
weight-based doses of RBV (1000–1200 mg/day) for 48 weeks
between 2003 and 2008. The patients were classified into
responders (patients with SVR, defined as undetectable HCV-
RNA in serum 24 weeks after treatment cessation) and non-
responders. Non-response was defined as continued presence of
HCV-RNA during therapy (null response), rebound of HCV-
RNA while on therapy (breakthrough) or 24 weeks after the end of
treatment (relapse). All virological analyses were performed using
serum specimens obtained before patients initiated treatment and
conserved at 280uC until testing.
Baseline clinical and epidemiological host parameters
Variables considered were gender, age, weight, source of
infection, stage of fibrosis according to the Scheuer scoring system
[42], and serum levels of ALT, AST, and GGT. Liver enzyme
levels were transformed into a quotient expressing the factor times
upper limit of normal (ULN) according to gender. We defined
good treatment adherence as having received $80% of total
maximum dose prescribed of both drugs for $80% of the
expected duration of therapy [43].
Baseline virological parameters
Serum viral load. HCV-RNA had been quantified by RT-
PCR (CobasH Amplicor HCV Monitor test, Roche Molecular
Systems, Pleasanton, CA, USA) or by real-time RT-PCR (Abbott
RealTime HCV assay, Abbott Molecular Inc., Des Plaines, IL,
USA), according to manufacturer’s instructions.
RNA extraction and reverse transcription (RT). Total
RNA was extracted from 220 ml of serum, using the QIAampH
viral RNA kit (QIAGENH GmbH, Hilden, Germany) according to
the manufacturer’s protocol. RT was performed using random
hexamers in order to prevent any bias during the reaction, as
previously described [44].
PCR-cloning and sequencing of the E1–E2 region. A 532-
bp sequence encompassing the E1 C-terminal and the E2 N-
terminal regions (including the HVR-1, HVR-2 and HVR-3) was
obtained and referred to as E1–E2 region (nucleotides 1322–1853
in the H77 reference sequence, GenBank accession number
AF009606). PCR products were cloned and sequenced as
previously described [44]. Briefly, a hemi-nested PCR was
carried out with the proofreading Pfu DNA polymerase
(Promega, Mannheim, Germany), and HCV-1b specific
degenerated primers (2-Eg1 and 2-Ea, and 2-Eg2 and 2-Ea
primers for the first and second rounds of PCR, respectively) [45].
Amplified DNA products were purified and cloned into EcoRV-
digested pBluescript II SK(+) phagemid (Stratagene, La Jolla, CA,
USA). Plasmids were transformed into Escherichia coli XL-1 blue
MRF’ competent cells (Stratagene). Between 25 and 35 colonies
were selected and subjected to PCR followed by purification and
sequencing of both strands using vector-based primers and the
BigDyeTM Terminator v3.1 Ready Reaction Cycle Sequencing
Kit on ABI Prism 3730 or 3100-Avant Genetic Analyzers (Applied
Biosystems Foster City, CA, USA). Readings were assembled and
edited with the STADEN package v1.6. [46].
PCR and direct sequencing of the Core region. The
whole Core region (573 bp, H77 positions 342–914) was amplified
using forward primer Cg1 (59 GCCATRGTGGTCTGCGGAAC
39, H77 positions 137–156), which was slightly modified from
primer CC11 [37], and reverse primer Ca (59 GTTGGA-
GCAGTCGTTCGTRA 39, H77 positions 949–968). PCR was
performed in 50 ml containing 5 ml of cDNA, 0.2 mM of each
dNTP, 0.4 mM of each primer, Pfu buffer and 0.6 U of Pfu DNA
polymerase (Promega). Thermocycler conditions were: 1 cycle at
94uC for 2 min, 35 cycles at 94uC for 1 min, 55uC for 2 min and
72uC for 3 min, and 1 cycle at 72uC for 7 min. PCR products
were directly sequenced with the Cg2 primer (59 GGGAG-
GTCTCGTAGACCGTGCAYCATG 39, H77 positions 318–
344), which was slightly modified from the Core-A1g primer [47],
and the Ca primer.
Phylogenetic analysis of the E1–E2 region. The complete
E1–E2 cloned region was subjected to phylogenetic analysis in
order to rule out potential contamination between specimens and
assess clustering of patients according to treatment outcome.
Sequences were aligned by ClustalW implemented in MEGA 4
[48]. jModeltest [49] was used to obtain the evolutionary model
that best fitted the data according to the Akaike Information
Criterion. This model was employed to reconstruct a maximum-
likelihood phylogenetic tree with PHYML [50]. RAxML software
was used for evaluating tree reliability on the basis of branch
support (1000 replicates) [51].
Genetic variability analysis of the E1–E2 region. Multiple
alignments were generated for each patient for the complete E1–
E2 region, and the HVR-1, HVR-2 and HVR-3 (H77 nucleotide
positions 1491–1571, 1761–1787, and 1632–1739, respectively).
The following genetic variability estimates were obtained for each
multiple alignment with DnaSP v4.50 [52]: total number of
polymorphic sites (S), total number of mutations (g), nucleotide
diversity corrected by Jukes-Cantor method (p), and number of
quasispecies variants (number of haplotypes, nHap). The number
of nonsynonymous substitutions per nonsynonymous site (Ka) and
Ks were obtained using the Nei-Gojobori method.
Amino acid composition analysis in the E1–E2 region.
This analysis aimed to detect any amino acid position in the E1–
E2 region that differed between groups but showed within-group
homogeneity. Consensus sequences were compared between
groups with the program VESPA [53] to obtain the
predominant sequence for each group. The VESPA output file
was employed to estimate the G-statistics in each amino acid
position as previously described [31], where p-values #0.05 were
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Amino acid composition analysis of the Core region.
Direct sequences obtained were analysed as described for the E1–
E2 region. Sequences were also aligned to assess the presence of
amino acid polymorphisms associated to treatment outcome.
Statistical analysis. Clinical and virological values were
compared between responders and non-responders in bivariate
analysis using Student’s t test or Mann-Whitney U test for
quantitative variables, and Chi-square or Fisher’s exact tests for
categorical variables. Data was expressed as mean 6 standard
deviation, median and range, or relative frequency. Values
between 1.5 and 3 inter-quartile range above/below the upper/
lower quartile of quantitative variables were identified as outliers.
Statistical models were developed to predict non-response. A
multivariate logistic regression analysis was performed, where
covariates included in the model were explanatory variables that
achieved a p-value ,0.20 on bivariate analyses. Variables which
presented high correlations with other variables (Spearman’s
correlation .0.7) were also excluded to avoid colinearity
problems. To obtain the final set of variables included in the
model we used a backward stepwise selection procedure [54]. OR
and CI95% were reported for significant variables. Two discrim-
inant analyses were also carried out [55]. In model 1 all covariates
analyzed but those which presented high correlations with other
variables were considered. Variables with a skewed distribution
were transformed using quadratic or Log transformations and
multivariate normality was tested using Henze-Zirkler’s test [56].
The final discriminant function was obtained using a backward
stepwise variable selection procedure. To assess how the results
obtained would generalize to an independent but similar data set,
each case was classified by the functions from all cases other than
that case (‘‘leave-one-out’’ cross-validation); this validation was
performed in the whole stepwise variable selection procedure. Chi-
square test was used to test the equality of covariance structures
across groups [57], considering a pooled covariance matrix when
the value was not significant at the 0.1 level. Model 2 included
covariates that achieved a p-value ,0.15 on bivariate analyses
with the goal to improve the cross-validation results. ROC curves
were obtained and the following parameters were calculated to
measure the effectiveness of prediction: AUC, sensitivity (propor-
tion of responders which are correctly identified), specificity
(proportion of non-responders which are correctly identified),
NPV and PPV. These parameters were also computed after cross-
validation taking into account all misclassified patients in any of
the 43 replications. Cut-off values that yielded highest sensitivity
and specificity were selected by ROC curve analysis for the three
predictive models obtained. P-values ,0.05 were considered
significant. Statistical analyses were performed using the statistical
software packages SPSS v15.0 and SAS v9.1 (SAS Institute Inc.,
Cary, NC, USA).
Accession numbers. All sequences obtained in this study
were submitted to the EMBL Nucleotide Sequence Database
(http://www.ebi.ac.uk/embl/) under the following accession
numbers: FN675941-FN675983, FN675984-FN676976, and
FN676977-FN677019 for Core, E1–E2 and NS5B regions,
respectively.
Supporting Information
Figure S1 All viral sequences obtained for each patient are
identified with a vertical line, the patient identification number
and the response group (R, responders; NR, non-responders).
Substitution model: GTR+G+I (gamma shape parameter: 0.926,
proportion of invariable sites: 0.271). All nodes corresponding to
each individual patient were supported with bootstrap values
.70%. The scale bar represents 0.05 substitutions per nucleotide
position.
Found at: doi:10.1371/journal.pone.0014132.s001 (0.02 MB
PDF)
Text S1
Found at: doi:10.1371/journal.pone.0014132.s002 (0.03 MB
DOC)
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